Wednesday, April 24, 2024 4/24/2024

Maternal Anti-myostatin (GDF8) Therapy to Enhance Offspring Musculoskeletal Health in Mouse Models of Osteogenesis Imperfecta

Award Number: R21AR077813
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Summary Osteogenesis imperfecta (OI) is a genetically and clinically heterogeneous connective tissue disorder resulting in muscle weakness, bone deformity and increased fragility, primarily due to type I collagen gene mutations. Currently there is no cure. Genetic and clinical heterogeneity (> 1500 mutations) and growing evidence of mutation specific pathogenesis further challenges drug discovery. Deficiency in myostatin, a circulating negative regulator of muscle growth, results in increased muscle mass and physiological loading on the skeleton with concomitant increases in bone mass and biomechanical integrity. Developmental programming by the prenatal environment is hypothesized to play a significant role in lifelong bone health and promises to provide a novel modality for therapeutic intervention. Congenital myostatin null mice demonstrate both myofiber hyperplasia and hypertrophy, while mice with postnatal myostatin deficiency exhibit only hypertrophy, indicating some aspects of adult physiology are irreversibly determined during prenatal development. Previously, by three independent approaches we demonstrated that reduced maternal myostatin during pregnancy improves bone geometry and biomechanical integrity in offspring: 1) Wildtype (Wt) offspring born to dams with reduced myostatin (+/mstn) had stronger bones than Wt offspring born to Wt dams; 2) Mice with osteogenesis imperfecta (+/oim) had stronger bones when born to +/mstn dams than when born to +/oim dams; and 3) +/oim blastocysts transferred to +/mstn recipient dams had stronger bones as adults than those transferred to +/oim dams. Importantly, the last approach through embryo transfer experiments demonstrated that the maternal +/mstn effect on offspring bone was conferred by the uteroplacental environment during pregnancy. Based on these findings, we will test the efficacy of pharmacological inhibition of maternal and fetal myostatin during pregnancy via maternal anti-myostatin (GDF8) monoclonal antibody treatment as a prenatal therapeutic approach for OI using two molecularly distinct OI mouse models. The primary outcomes measures and indicators of efficacy are improved musculoskeletal health (skeletal muscle and bone mass and function) of Wt and OI offspring at the age of peak bone mass (4 month old). OI can be diagnosed prenatally, whether genetically or by ultrasound, yet we have no prenatal treatment options and, are thus missing a critical therapeutic window. This high risk study represents a more than incremental leap towards establishing the translational potential of a prenatal treatment for OI, it is a paradigm shift in understanding and treating OI; a shift from believing only genetic and postnatal factors control bone health, to the inclusion of the prenatal/perinatal period as an important and modifiable window for controlling adult bone health.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$6 )
2024	2021	UNIVERSITY OF MISSOURI SYSTEM	121 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	2/15/2024	NON-COMPETING CONTINUATION	-$6
														Subtotal = -$6

Issue Date FY: 2021 ( Subtotal = $164,451 )
2021	2021	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	2	7/30/2021	SUPPLEMENT FOR EXPANSION	$59,028
2021	2021	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	6/18/2021	NON-COMPETING CONTINUATION	$164,451
2021	2021	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	002	2	8/26/2021	SUPPLEMENT FOR EXPANSION	-$59,028
														Subtotal = $164,451

Issue Date FY: 2020 ( Subtotal = $203,666 )
2020	2020	UNIVERSITY OF MISSOURI SYSTEM	316 UNIVERSITY HALL	COLUMBIA	MO	65211	BOONE	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	7/14/2020	NEW	$203,666
														Subtotal = $203,666

Grand Total All Awards = $368,111

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Maternal Anti-myostatin (GDF8) Therapy to Enhance Offspring Musculoskeletal Health in Mouse Models of Osteogenesis Imperfecta

Award Number: R21AR077813

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer